1. Home
  2. PHVS vs DK Comparison

PHVS vs DK Comparison

Compare PHVS & DK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • DK
  • Stock Information
  • Founded
  • PHVS 2015
  • DK 2001
  • Country
  • PHVS Switzerland
  • DK United States
  • Employees
  • PHVS N/A
  • DK N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • DK Integrated oil Companies
  • Sector
  • PHVS Health Care
  • DK Energy
  • Exchange
  • PHVS Nasdaq
  • DK Nasdaq
  • Market Cap
  • PHVS 909.5M
  • DK 1.0B
  • IPO Year
  • PHVS 2021
  • DK 2006
  • Fundamental
  • Price
  • PHVS $16.49
  • DK $18.85
  • Analyst Decision
  • PHVS Strong Buy
  • DK Hold
  • Analyst Count
  • PHVS 5
  • DK 12
  • Target Price
  • PHVS $39.20
  • DK $17.11
  • AVG Volume (30 Days)
  • PHVS 59.6K
  • DK 1.8M
  • Earning Date
  • PHVS 05-13-2025
  • DK 05-07-2025
  • Dividend Yield
  • PHVS N/A
  • DK 5.41%
  • EPS Growth
  • PHVS N/A
  • DK N/A
  • EPS
  • PHVS N/A
  • DK N/A
  • Revenue
  • PHVS N/A
  • DK $11,366,100,000.00
  • Revenue This Year
  • PHVS N/A
  • DK N/A
  • Revenue Next Year
  • PHVS N/A
  • DK N/A
  • P/E Ratio
  • PHVS N/A
  • DK N/A
  • Revenue Growth
  • PHVS N/A
  • DK N/A
  • 52 Week Low
  • PHVS $11.51
  • DK $11.03
  • 52 Week High
  • PHVS $25.50
  • DK $25.83
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 51.83
  • DK 62.03
  • Support Level
  • PHVS $15.46
  • DK $18.92
  • Resistance Level
  • PHVS $16.99
  • DK $20.21
  • Average True Range (ATR)
  • PHVS 1.04
  • DK 1.05
  • MACD
  • PHVS -0.08
  • DK 0.04
  • Stochastic Oscillator
  • PHVS 71.48
  • DK 61.69

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About DK Delek US Holdings Inc.

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. Delek's logistics segment sells portions of the petroleum products its refineries produce. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

Share on Social Networks: